Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis  by Nathan, Steven D. et al.
Respiratory Medicine (2010) 104, 1035e1041ava i lab le at www.sc ienced i rec t . com
journa l homepage : www.e lsev ier . com/ loca te / rmedPrevalence and impact of coronary artery disease in
idiopathic pulmonary fibrosis*Steven D. Nathan a,*, Ashwin Basavaraj b, Cristina Reichner b,
Oksana A. Shlobin a, Shahzad Ahmad a, Joseph Kiernan a,
Nelson Burton a, Scott D. Barnett aa Inova Transplant Center, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
b Georgetown University Medical Center, Washington, DC, USA
Received 27 October 2009; accepted 9 February 2010
Available online 2 March 2010KEYWORDS
Pulmonary fibrosis;
Coronary artery disease;
Pulmonary disease;
Chronic obstructive;
Heart catheterizationAbbreviations: CAD, coronary artery
pulmonary fibrosis; LHC, left heart ca
* This study was unfunded. None of
* Corresponding author. Tel.: þ1 (70
E-mail address: steven.nathan@ino
0954-6111/$ - see front matter ª 201
doi:10.1016/j.rmed.2010.02.008Summary
Introduction: Idiopathic Pulmonary Fibrosis (IPF) is a progressive disease with a poor prognosis
for which there is no effective medical therapy. An awareness of comorbidities that are treat-
able and might impact outcomes in these patients is therefore very important. We sought to
determine the prevalence of coronary artery disease (CAD) in IPF patients in comparison to
a control group of patients with chronic obstructive pulmonary disease (COPD). We also sought
to assess the impact of CAD on IPF patient outcomes.
Patients and methods: IPF and COPD transplant candidates whose work-up included left heart
catheterization were categorized as having significant CAD, non-significant CAD or no disease.
The risk factor profile and prevalence of CAD in both groups was compared.
Results: There were 73 IPF and 56 COPD patients. The prevalence of CAD was 65.8% in the IPF
group compared to 46.1% in the COPD patients (p< 0.028). Significant disease was present in
28.8% of IPF patients vs.16.1% of the COPD patients (p< 0.081). Unsuspected significant CAD
was found in 18% of IPF patients versus 10.9% of COPD patients (p< 0.004). Outcomes of IPF
patients with significant CAD was worse than those with no or non-significant disease
(p< 0.003) with a median survival of 572 days from the time of left heart catheterization.
Conclusion: There is a higher prevalence of CAD in IPF patients compared to a similarly
matched COPD group. This increased association appeared to be independent of common coro-
nary artery risk factors. IPF patients with significant CAD appear to have worse outcomes.
ª 2010 Elsevier Ltd. All rights reserved.disease; CI, confidence interval; COPD, chronic obstructive pulmonary disease; IPF, idiopathic
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Table 1 Demographics of the IPF and COPD patients.
IPF (NZ 73) COPD (NZ 56) P
Age (mean SD) 60.1 6.1 59.3 5.9 0.453
Male Sex (%) 55 (75.3) 26 (45.6) 0.001
Caucasian 58 (79.5) 36 (63.2) 0.049
Body Mass
Index, kg/m2
28.6 4.4 26.1 5.1 0.003
FVC% 60.2 15.0 54.3 16.3 0.034
FEV1% 63.5 14.5 27.4 11.6 0.001
DLCO% 33.9 14.9 33.8 15.6 0.970
DLCOZ carbon monoxide diffusion capacity; FVCZ forced vital
capacity; FEV1Z forced expiratory volume.
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Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic
disorder of the lungs with an estimated prevalence
between 14 and 42.7 per 100,000 in the USA.1 Recent
evidence suggests that the incidence and overall mortality
from IPF is increasing.1e3 The peak incidence was formerly
thought to be in the 5th or 6th decade of life, but there is
a growing appreciation that IPF is a disease of the elderly
with the highest incidence in those older than 75.1,4
Whereas previously IPF was regarded as having an inflam-
matory pathogenesis, it is now commonly held to be
a disease of disordered repair with the main progenitors of
the disease being activated fibroblasts and myofibroblasts.5
The unbridled proliferation of these cells is seen in
conjunction with derangements in cytokine and chemokine
expression. Whether these constituents of the disease have
local effects only or whether they might result in systemic
sequelae has led to speculation of a link between IPF and
coronary artery disease (CAD).6e9
The clinical course of IPF is one of progressive deterio-
ration with significant mortality and a median survival of
2.5e3.5 years.10 It is possible that co-existing morbidities
contribute to some of this mortality. Older patients have
been shown to have a significantly worse prognosis with
a worse survival.2,11 Whether this is a function of the disease
or a higher prevalence of comorbid conditions is uncertain.
We have previously noted that patients with IPF being
evaluated for lung transplantation have a higher prevalence
of CAD than patients with chronic obstructive pulmonary
disease (COPD) being similarly evaluated.12 We therefore
sought to validate this finding from prospectively collected
data in subsequent patients with IPF and COPD. We also
sought to establish whether IPF was an independent risk
factor for CAD and whether underlying CAD impacted the
outcomes of patients with IPF.
Methods
Our previously performed retrospective analysis included
all IPF transplant candidates who had undergone left heart
catheterization (LHC) as part of their pretransplant evalu-
ation for the period October 1996 to August 2003. For the
current study we analyzed data from IPF and COPD (control
group) patients who were seen and evaluated for lung
transplantation for the subsequent period from September
2003 to July 2008. IPF patients were diagnosed as per the
American Thoracic Society/European Respiratory Society
guidelines.13 Commonly recognized risk factors for coronary
artery disease were also collated. These included a history
of smoking, hypertension, diabetes mellitus, hypercholes-
terolemia and a family history of CAD. In addition, it was
noted whether patients had a history of CAD prior to their
routine pretransplant LHC. Based on the results of the LHC,
patients were categorized as having significant CAD (need
for an intervention or major vessel with >50% lesion), non-
significant CAD (< 50% occlusion of major vessel or disease
of smaller vessels) or no disease. Lastly, we determined the
mortality of those IPF patients with significant CAD versus
those with no or non-significant CAD. This study was
approved by the Inova Institutional Review Board.Statistics
Continuous data are presented as mean and range or
standard deviation. Categorical data are presented as
frequency and percent. Continuous data were tested for
statistical significance via Students’ t-test or One-Way
Anova, where appropriate. Categorical data were tested
via chi-square. Unconditional logistic regression models
were used to generate odds ratios (OR) and 95% confidence
intervals (CI). KaplaneMeier survival curves were used to
explore associations between disease status and significant
CAD with the log-rank test used to determine statistical
significance. Cumulative probability of death after cardiac
catheterization was calculated using Cox proportional
hazards models to allow for the adjustment of potential
confounders such as age, body mass index, gender, forced
vital capacity percent predicted, and single breath
diffusing capacity for carbon monoxide percent predicted.
Hazard ratios (HR) are presented along with 95% CI.
Statistical significance was set at p< 0.05 All statistical
analyses were conducted using GraphPad Prism (Version
4.0, San Diego CA) and SAS (Version 9.2, Cary NC).
Results
There were 73 IPF patients and 56 COPD patients who
qualified for the analysis. The demographics of the two
groups are shown in Table 1. The diagnosis of IPF was
confirmed in 41/73 (56.2%) of patients by surgical lung
biopsy. Of the 73 IPF patients, 27 subsequently underwent
lung transplantation. The diagnosis of IPF was confirmed in
all of these with no alternate diagnosis suggested by
histopathologic examination of the explants. Seventeen of
these patients were in the group that had not had prior
surgical lung biopsies. Therefore there was histopathologic
evidence of IPF in 80.8% (59/73) IPF patients. In all cases
where there was no tissue confirmation of the diagnosis,
the ATS/ERS diagnostic criteria for IPF were fulfilled,
including having CT scans showing changes typical of the
disease. The diagnosis of COPD was made by a combination
of clinical presentation and pulmonary function data. In
addition, in all cases CT scans were obtained which showed
changes consistent with emphysema.
The prevalence of CAD was 65.8% in the IPF group
compared to 46.1% of COPD patients (p< 0.028) (Fig. 1).
Significant disease was present in 21 (28.8%) IPF patients
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Figure 1 Coronary artery disease status of IPF (NZ 73) and
COPD (NZ 56) patients as defined by left heart catheteriza-
tion. Abbreviations: CADZ coronary artery disease, NSZ non-
significant.
Coronary artery disease in IPF 1037compared to 9 (16.1%) of the COPD patients (p< 0.081).
Non-significant disease was present in 27 (37%) of the IPF
patients and 17 (30%) of the COPD patients (p< 0.392). The
demographics of the IPF subgroups with no CAD, non-
significant CAD and significant CAD are shown in Table 2.
Patients with significant CAD were older and all the patients
with non-significant disease were Caucasian. Of the 73 IPF
patients, 12 (16.4%) had LHC prior to being evaluated for
lung transplantation. Of these 12 patients, 1 had significant
disease, 5 had non-significant disease and 6 had no disease.
A further 9 IPF patients were known to have CAD. There-
fore, prior to transplant evaluation, 20.5% (15/73) of IPF
patients as compared to 17.9% (10/56) of COPD patients
were known to have CAD. In patients with unknown CAD
status, 63.5% (33/52) of the IPF patients were found to have
some form of CAD at LHC, compared to 34.8% (16/46) of the
COPD cases (p< 0.005, Fig. 2). Significant CAD was found in
21.2% (11/52) of these IPF patients compared to 10.9%
(5/46) of the COPD patients (p< 0.169). For patients >60
years of age, the prevalence of CAD was 70% (28/40) and
56.5% (13/23) in the IPF and COPD patients, respectively
(p< 0.280). Significant CAD accounted for 54% (15/28) andTable 2 Demographics of IPF patients with unknown corona
(NZ 52).
CAD Classification
None (NZ 19) Non-sign
Age (mean SD) 59.7 5.9 58.7 5
Male (%) 14 (73.7) 16 (72.7
Caucasian 14 (73.7) 22 (100)
Body Mass Index, kg/m2 27.9 5.2 29.5 3
FVC% 57.6 13.3 64.6 1
FEV1% 61.7 12.1 67.8 1
DLCO% 31.4 9.4 36.0 1
CADZ coronary artery disease; DLCOZ carbon monoxide diffusion c
volume; SDZ standard deviation.
a Non-significant CADZ<50% occlusion of major vessel or disease o
b Significant CADZ need for an intervention or major vessel with >21.7% (5/23) of these cases in the two groups (p< 0.021).
Significant CAD was present in 5/14 (35.7%) of IPF patients
who were diagnosed clinically versus 16/59 (27.1%) of
patients in whom there was tissue confirmation of the
diagnosis (p< 0.527).
Significant between group demographic differences
were observed for male gender (IPF, 75.3% vs. COPD, 45.6%,
p< 0.001), Caucasian (79.5% vs. 63.2%, p< 0.049), BMI
(28.6 vs. 26.1, p< 0.003), and FEV1% (63.5% vs. 27.4%,
p< 0.001). A logistic regression model predicting CAD with
adjustment for potential cofounders demonstrated that
they did not significantly alter the influence of IPF status in
the prediction of CAD. For the IPF patients, there were 10
patients with 3 or more risk factors for CAD, 24 with 2 risk
factors, 25 with one risk factor and 14 with no risk factors.
The prevalence of CAD amongst these groups is shown in
Table 3. Compared to COPD, the diagnosis of IPF was
predictive of CAD status (OR: 2.21; 95% CI: 1.09e4.53) prior
to adjustment and nearly significant after adjustment (OR:
1.67; 95% CI: 0.59e4.78) for age, male gender, hyperten-
sion, hypercholesterolemia, diabetes, history of smoking,
and a family history of CAD (C-statisticZ 0.69) (Table 4). It
is noteworthy that no adjusted demographic or clinical co-
morbidity was statistically significant in this final model.
Of the 11 IPF patients with unknown significant CAD prior
to evaluation, surgery or stent placement was performed or
recommended in 4 patients while the rest were managed
medically. Of the 10 patients with known significant CAD, 3
had prior coronary artery bypass grafting and 2 had previ-
ously had coronary stents placed. Despite these interven-
tions, KaplaneMeier survival analyses revealed worse
outcomes for those patients with IPF and significant CAD
compared to those with no or non-significant CAD. The first
analysis included 26 patients who received lung transplants
with these patients censored as alive at the time of trans-
plant (p< 0.003, Fig. 3). A second survival analysis was
performed with transplant recipients excluded and this still
showed a significant difference in outcomes in favor of
those with non-significant or no CAD (p< 0.026).
Unadjusted Cox proportional hazard models suggested
that from among modeled parameters including age,
gender, body mass index, pulmonary function parameters
(forced vital capacity (FVC) and diffusing capacity percentry artery disease status prior to left heart catheterization
ificanta (NZ 22) Significantb (NZ 11) P
.7 65.0 5.2 0.013
) 10 (90.9) 0.462
7 (63.6) 0.015
.6 27.9 4.5 0.443
5.3 57.8 19.9 0.299
5.6 59.9 14.4 0.232
8.0 35.1 15.2 0.596
apacity; FVCZ forced vital capacity; FEV1Z forced expiratory
f smaller vessels.
50% lesion.
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Figure 2 Coronary artery disease (CAD) status as defined by
left heart catheterization in those IPF (NZ 61) and COPD
(NZ 46) patients in whom CAD status was unknown at the time
of the catheterization. Abbreviations: CADZ coronary artery
disease, NSZ non-significant.
1038 S.D. Nathan et al.predicted (DLCO)), mean pulmonary artery pressure,
significant CAD and IPF status, only significant CAD
(HR: 3.30; 95% CI: 1.11e9.83) and IPF (HR: 7.45; 95% CI:
2.19e25.51) status were predictive of mortality (Table 5).
After adjustment for aforementioned potential
confounders, male, age, FVC% predicted, DLCO % predicted,
only IPF status remained a significant predictor of death
(HR: 20.22; 95% CI: 2.41e169.32). Although CAD status lost
statistical significance after adjustment, there was still
a trend towards significance (HR: 4.49; 95% CI: 0.95e21.36).
No interaction between IPF status and significant CAD was
evident (Fig. 4).
Discussion
In our study, we confirm the association of IPF with CAD by
comparing a well characterized group of IPF patients with
a control cohort of COPD subjects. We sought to explore
this relationship in greater depth by collating and assessing
the influence of traditional CAD risk factors. From amongst
these, the only difference between the two groups was in
cigarette smoking which was more prevalent in the COPD
subjects. Therefore, one might have expected a greater
prevalence of CAD in this group rather than the IPF
patients, which serves to underscore the significance of our
findings. In addition, our multivariate analysis accountingTable 3 Number of risk factors in relation to the prior known
patients (NZ 73).
Risk factors No. patients Known CAD
3 10 5 (50%)
2 24 5 (20.8%)
1 25 2 (8.0%)
0 14 3 (21.4%)
Abbreviations: CADZ coronary artery disease; No.Z number of.for the more commonly recognized CAD risk factors, still
suggested that IPF was an independent risk factor. We
further demonstrate that the presence of significant CAD in
IPF patients might be associated with an increased
mortality with a strong trend towards significance after
accounting for other recognized important prognostic
factors through our multivariate analysis.
There have been many advances in the understanding of
the pathogenesis of IPF in recent years. These have not as
yet translated into any effective therapies and the prog-
nosis of this condition remains quite poor. The fibrotic
process that characterizes IPF is confined to the lungs, but
there is an increasing recognition that IPF may be associ-
ated with a higher propensity for certain comorbidities,
including a greater predilection for CAD.6e9,14e17 The
explanation for the association between IPF and CAD is
open to conjecture. Kizer and associates hypothesized
three possible mechanisms: a common offending agent,
a shared proclivity to fibrosis or a direct causal relationship
between the two entities.6 The first of these appears
unlikely while the second might be possible, since IPF and
CAD are both diseases associated with excessive fibrosis.6
The pathogenesis of arteriosclerosis has similarities to
that of IPF as it may be initiated by a denuded endothelium
similar to the alveolar epithelial disruption described in IPF.
The ensuing chronic inflammation may result in a compli-
cated lesion and ultimately fibrosis of the artery.18 A direct
causal relationship between the two entities is also an
appealing hypothesis. Both diseases ‘‘share’’ common
cytokines that are upregulated and might be important in
priming the milieu, thereby fostering the co-development
of each disease. Also, intermittent hypoxemia represents
a form of oxidative stress which may injure the endothe-
lium and trigger atherogenesis.19
To our knowledge, there is no data looking at the prev-
alence of CAD in the general population as defined by left
heart catheterization. However, estimates of the preva-
lence of CAD in patients age 55e64 in the US population as
a whole, are 13.1% in men and 8.4% in women.20 This is
much lower than the prevalence found in our IPF patients.
Since it was not feasible to have normal controls for
comparison, we elected to use COPD patients for our
comparative arm. This group appeared to most closely
approximate our IPF patients in their demographic profile.
In addition, one might have expected a higher prevalence
of CAD in these patients by virtue of their greater exposure
to cigarette smoking and the previously documented asso-
ciation of this disease with atherosclerosis.21,22 On the
other hand, the greater proportion of males in the IPFpresence and unknown coronary artery disease status in IPF
Unknown CAD status, CAD classification
None Non-significant Significant
1 (10%) 2 (20%) 2 (20%)
5 (20.8%) 8 (33.3%) 6 (25%)
8 (32.0%) 13 (52.0%) 2 (8.0%)
4 (28.6%) 6 (42.9%) 1 (7.1%)
Table 4 Unadjusted and adjusted logistic regression
models of factors predictive of coronary artery Disease in
IPF and COPD patients.
Unadjusted Adjusted
Age 1.05 (0.99e1.19) 1.05 (0.98e1.12)
Male 1.85 (0.90e3.81) 1.74 (0.78e3.94)
BMI (kg/m2) 1.05 (0.97e1.14) 1.01 (0.93e1.10)
Hypertension 1.65 (0.82e3.39) 1.84 (0.82e4.08)
Hypercholesterolemia 2.36 (0.92e6.12) 2.03 (0.71e5.76)
Diabetes 3.67 (0.76e17.72) 2.61 (0.48e14.22)
History of smoking 1.82 (0.85e3.86) 1.02 (0.36e2.91)
Family history
of CAD
4.76 (0.55e40.75) 1.74 (0.18e16.77)
IPF statusa 2.21 (1.09e4.53) 1.67 (0.59e4.78)
CADZ coronary artery disease; ORZ odds ratio; and CIZcon-
fidence interval.
a IPF status relative to COPD.
Table 5 Unadjusted and adjusted proportional hazard
models for the prediction of mortality.
Unadjusted HR
(95% CI)
Adjusted HR
(95% CI)a
Age (years) 1.02 (0.95e1.09) 0.99 (0.92e1.06)
BMI 1.01 (0.92e1.12) 0.94 (.083e1.06)
FVC % predicted 1.02 (0.98e1.04) 0.99 (0.96e1.03)
Mean PA pressure
(mmHg)
1.02 (0.97e1.07) 1.04 (0.97e1.12)
DLCO % predicted 1.00 (0.97e1.03) 0.98 (0.93e1.04)
Male gender 1.74 (0.68e4.49) 1.90 (0.46e7.94)
Significant CAD 3.30 (1.11e9.83) 4.83 (0.90e26.03)
IPF 7.45 (2.19e25.51) 22.74 (2.54e203.17)
BMIZ body mass index; CADZ coronary artery disease;
DLCOZ carbon monoxide diffusion capacity; FVCZ forced vital
capacity; PAZ pulmonary artery; and HRZ hazard ratio.
a Adjusted for all other terms in the table.
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Coronary artery disease in IPF 1039cohort might have contributed to the greater prevalence of
CAD in this group. However, the inclusion of gender within
our Cox models demonstrated little impact on the IPF
estimates.
It has previously been shown that cardiovascular disease
does account for some of the mortality of patients with IPF.
Indeed, CAD along with other cardiovascular comorbidities
such as congestive heart failure and stroke has been
reported to account for 27% of deaths in IPF patients.14
However, our study is the first to suggest that IPF patients
with significant CAD documented via left heart catheteri-
zation might have worse outcomes.Although it might be
expected that patients with significant CAD would have
worse outcomes than those without, in the context of
a deadly disease which is more likely to drive mortality, this
is somewhat of a surprise. The heightened mortality risk
might be related to the interplay and negative cascade of
the two diseases; specifically, it is possible that patients
with pre-existing CAD are less likely to tolerate hypoxic
episodes and therefore might be at greater risk for cardiac
events. Those patients who were discovered to have
significant CAD were treated medically and in some cases
with further interventions, including stent placement or
coronary artery bypass grafting. Despite these interven-
tions, the presence of CAD still appeared to adversely0 250 500 750 1000 1250 1500 1750 2000
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Figure 3 IPF survival comparison of patients with significant
coronary artery disease to those with non-significant or no
coronary artery disease.impact outcomes. It is likely that undiagnosed significant
CAD, which represented 18% of our population, would have
an even more profound impact on outcomes if left
untreated. It is noteworthy that the prognosis of our cohort
with mild or no CAD was significantly better than the
historical reported survival of patients with IPF. A possible
explanation contributing to this is that some of the patients
in these prior studies had unrecognized CAD that may have
placed them at higher risk of mortality.2,11
Our findings might have important implications for the
management of patients with IPF. In the context of a deadly
disease without known, proven effective therapy, the
ability to potentially impact the course of nearly 20% of the
patients by ruling out and treating significant CAD is an
important consideration. Most of our patients were rela-
tively young since the majority of the LHCs were obtained
as part of a lung transplant evaluation. The mean age of our
cohort was 60 years with 98.6% (72/73) age 70. We
speculate that the prevalence of CAD would be even higher
in older patients with IPF. Whether the worse outcomes of
older patients with IPF is due to a delay in the diagnosis,
more aggressive disease, reduced pulmonary reserve or0 250 500 750 1000 1250 1500
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Figure 4 Results of Cox proportional hazards model adjust-
ing for IPF (p< 0.008), CAD (p< 0.059), male (p< 0.479), age
(p< 0.565), FVC% predicted (p< 0.744), and DLCO% predicted
(p< 0.358). Abbreviations: IPFZ idiopathic pulmonary
fibrosis; CADZ coronary artery disease; FVCZ forced vital
capacity; and DLCOZ single breath diffusing capacity for
carbon monoxide.
1040 S.D. Nathan et al.a result of comorbidities is uncertain. Our findings with
regards to CAD in IPF, and the likely higher incidence in
elderly IPF patients, suggest that CAD might contribute to
this noted worse prognosis.
Despite demonstrating worse survivals for those patients
with significant CAD, we did not prove that its detection
and treatment impacted survival. However, it does make
intuitive sense that this might be the case. We therefore
contend that there should a high index of suspicion for CAD
in patients with IPF, especially elderly patients in whom
episodes of shortness of breath could represent anginal
equivalents. Although we assessed our patient population
by left heart catheterization, it is possible that a less
invasive cardiac stress test might suffice as a screen.23e25
There are several limitations to our study. Our relative
small sample size and select nature of our patient population
makes it difficult to extrapolate these findings to all IPF
patients. Strengths of our study include our well-
characterized IPF population and the fact that we did
account for other common cardiac risk factors and risk
factors for death through our multivariate analyses. Our
choice of COPD patients as a comparative group could also
be criticized if one were to argue that the higher prevalence
of CAD in IPF might be due to COPD somehow being
‘‘protective’’ of CAD. This scenario is highly unlikely since, in
addition to our COPD patients having a higher prevalence of
smoking, there is also emerging data that COPD itself is
associated with a heightened risk of cardiovascular compli-
cations.21,22,26 Therefore, comparison to a normal pop-
ulation might have resulted in an even greater difference.
There were some differences in the baseline characteristics
of the two groups and we cannot categorically exclude these
could have accounted for some of the differences in the
prevalence of CAD described. However, our multivariate
modeling suggests that this was not the case, although our
study was not powered to explore these relationships.
In summary, our study confirms an association between
CAD and IPF which appears to be independent of commonly
recognized coronary risk factors. Co-existing CAD appears
to be associated with increased mortality in IPF patients,
despite appropriate therapeutic intervention. Screening for
occult CAD, not only in potential lung transplant candi-
dates, but also in other patients with IPF appears to be an
important consideration. We speculate that aggressive
therapeutic intervention for documented CAD could have
a significant impact on the survival of IPF patients with this
accompanying co-morbidity.
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